Yahoo
Shanghai - Delayed Quote CNY

Tasly Pharmaceutical Group Co., Ltd (600535.SS)

13.82 +0.21 (+1.54%)
At close: October 30 at 3:00:01 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
7,999,455.95
8,236,477.44
8,498,141.86
8,674,014.17
8,637,429.22
Cost of Revenue
2,560,173.04
2,729,994.13
2,792,252.55
2,880,102.76
3,120,919.19
Gross Profit
5,439,282.91
5,506,483.30
5,705,889.31
5,793,911.41
5,516,510.03
Operating Expense
3,639,831.85
4,052,009.18
4,211,413.22
4,289,106.10
4,150,775.79
Operating Income
1,799,451.06
1,454,474.12
1,494,476.09
1,504,805.31
1,365,734.24
Net Non Operating Interest Income Expense
33,753.82
24,319.40
26,247.78
20,286.52
-28,418.17
Pretax Income
1,463,521.67
1,345,215.75
1,068,689.80
1,221,096.56
-167,632.19
Tax Provision
307,723.30
283,885.50
209,634.22
204,456.51
180,823.16
Net Income Common Stockholders
1,223,159.93
1,104,961.93
955,586.17
1,071,072.34
-264,238.34
Basic EPS
0.82
0.74
0.64
0.72
-0.18
Diluted EPS
0.82
0.74
0.64
0.72
-0.18
Basic Average Shares
1,492,056.69
1,493,191.79
1,493,103.39
1,487,600.48
1,467,990.80
Diluted Average Shares
1,492,056.69
1,493,191.79
1,493,103.39
1,487,600.48
1,467,990.80
Total Operating Income as Reported
1,475,117.39
1,354,968.27
1,075,922.53
1,227,879.83
-160,082.22
Total Expenses
6,200,004.89
6,782,003.32
7,003,665.77
7,169,208.85
7,271,694.98
Net Income from Continuing & Discontinued Operation
1,223,159.93
1,104,961.93
955,586.17
1,071,072.34
-264,238.34
Normalized Income
1,348,439.36
1,057,217.86
1,244,388.91
1,225,143.08
871,076.55
Interest Income
47,706.40
58,341.24
91,050.05
107,545.19
40,632.94
Interest Expense
14,688.95
32,495.52
61,281.97
82,524.36
64,410.99
Net Interest Income
33,753.82
24,319.40
26,247.78
20,286.52
-28,418.17
EBIT
1,478,210.62
1,377,711.26
1,129,971.77
1,303,620.92
-103,221.19
EBITDA
1,478,210.62
1,832,374.14
1,626,169.94
1,808,532.07
414,730.32
Reconciled Cost of Revenue
2,560,173.04
2,729,994.13
2,792,252.55
2,880,102.76
3,120,919.19
Reconciled Depreciation
475,200.22
454,662.88
496,198.17
504,911.15
517,951.52
Net Income from Continuing Operation Net Minority Interest
1,223,159.93
1,104,961.93
955,586.17
1,071,072.34
-264,238.34
Total Unusual Items Excluding Goodwill
-158,634.21
60,514.69
-359,278.89
-185,055.91
-1,513,753.20
Total Unusual Items
-158,634.21
60,514.69
-359,278.89
-185,055.91
-1,513,753.20
Normalized EBITDA
1,636,844.83
1,771,859.46
1,985,448.84
1,993,587.98
1,928,483.52
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-33,354.78
12,770.62
-70,476.16
-30,985.17
-378,438.30
12/31/2022 - 8/23/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: